Table 1 Demographics and clinical characteristics of subjects

Age (years)

47.55 ± 15.33

47.53 ± 15.43

44.00 ± 14.32

58.59 ± 13.69^{†, ‡}

Gender (male/female)

120/153

40/51

26/43

14/8^‡

BMI (kg/m²)

23.58 ± 3.38

23.57 ± 3.49

23.18 ± 3.41

24.95 ± 3.49^‡

HGB (g/L)

141.99 ± 13.60

138.23 ± 17.39

138.48 ± 16.61

137.45 ± 20.34

LEU^*(*10⁹/L)

1.73 ± 0.24

1.59 ± 0.32^†

1.59 ± 0.32^†

1.58 ± 0.32^†

LYM%

35.92 ± 7.90

32.54 ± 10.46^†

34.17 ± 9.72

27.43 ± 11.27^{†, ‡}

eGFR^* (ml/min*1.73m²)

4.70 ± 0.15

4.66 ± 0.15^†

4.68 ± 0.15

4.57 ± 0.13^{†, ‡}

AST^* (U/L)

3.06 ± 0.29

3.03 ± 0.39

2.96 ± 0.36

3.24 ± 0.41^{†, ‡}

ALB/GLB

1.74 ± 0.24

1.35 ± 0.22^†

1.38 ± 0.22^†

1.24 ± 0.18 ^{†, ‡}

α-HBDH^* (U/L)

4.91 ± 0.17

4.90 ± 0.23

4.84 ± 0.20^†

5.06 ± 0.24^{†, ‡}

LDH^* (U/L)

5.14 ± 0.18

5.14 ± 0.25

5.08 ± 0.22^†

5.32 ± 0.26^{†, ‡}

FPG (mmol/L)

4.66 (4.39–5.05)

5.31 (4.890–6.18) ^†

5.06 (4.830–5.81) ^†

5.80 (5.340–7.36) ^{†, ‡}

PaO₂/FiO₂^*

–

5.94 ± 0.53

6.19 ± 0.25

5.12 ± 0.36^‡

Days from onset to admission

–

3.0 (1.0–6.0)

3.0 (1.00–6.0)

4.0 (1.750–6.0)

Days from admission to PCR negative)

–

9.0 (4.00–13.0)

8.0 (4.00–10.0)

11.50 (4.750–20.75) ^‡

Diabetic patients (%)

0

9 (9.9)

4 (5.8)

5 (22.7) ^‡

Gout patients (%)

0

0

Hypertensive patients (%)

0

17 (18.7)

10 (14.5)

7 (31.8)

 Total

5.80 ± 0.24

5.65 ± 0.28^†

5.66 ± 0.29^†

5.62 ± 0.25^†

 Male

5.95 ± 0.18

5.78 ± 0.26^†

5.86 ± 0.20^†

5.61 ± 0.28^{†, ‡}

 Female

5.68 ± 0.21

5.55 ± 0.26^†

5.53 ± 0.26^†

5.63 ± 0.20

 Total

4.14 ± 0.20

4.10 ± 0. 26

4.08 ± 0.27

4.16 ± 0.22

 Male

4.31 ± 0.13

4.30 ± 0.21

4.32 ± 0.22

4.26 ± 0.19

 Female

4.01 ± 0.14

3.94 ± 0.18

3.93 ± 0.19^†

4.00 ± 0.15

 Total

1.65 ± 0.20

1.55 ± 0.27^†

1.58 ± 0.24^†

1.45 ± 0.32^†

 Male

1.64 ± 0.20

1.48 ± 0.28^†

1.54 ± 0.23^†

1.35 ± 0.34^{†, ‡}

 Female

1.67 ± 0.21

1.60 ± 0.24^†

1.60 ± 0.25

1.63 ± 0.18